糖尿病前期子组,2型糖尿病风险,以及预防干预措施的差异效应
Jeanette M Stafford1, Ramon Casanova1, Byron C Jaeger1
1Wake Forest University School of Medicine.
The Journal of clinical endocrinology and metabolism
|June 11, 2025
概括
研究人员确定了两个糖尿病前期子组,具有明显的糖尿病风险和干预益处. 甲胺在高风险小组中显示出更大的益处,这表明了针对2型糖尿病的个性化预防策略.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 临床生物标志物 临床生物标志物
背景情况:
- 前糖尿病的分类是有限的,阻碍了个性化的预防策略.
- 很少有研究评估了糖尿病前期亚组之间的差异性干预效应.
研究的目的:
- 使用临床生物标志物推导出糖尿病前期子组.
- 在子组内评估糖尿病风险和预防性干预效应.
- 将聚类方法与更简单的建模进行比较.
主要方法:
- 在3145名糖尿病预防计划参与者中,K意味着22个生物标志物的聚类.
- 对于糖尿病风险和干预效应的考克斯比例危险回归.
- 集群策略与临床变量模型的比较.
主要成果:
- 确定了两个子组:严重的胰岛素抵抗/肥胖 (31%) 和中度的胰岛素抵抗/超重 (69%).
- 高危子组的糖尿病风险增加了58%.
- 生活方式干预降低了两者的风险一半;在高风险小组中,甲胺的益处更大 (p<0.05).
- 临床变量模型在糖尿病风险歧视方面表现优于聚类.
结论:
- 病理生理学上不同的糖尿病前期亚组表现出不同的糖尿病风险和甲福林反应.
- 结果表明不同的糖尿病易感机制.
- 临床预测模型可以充分描述治疗指导的风险.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes: Symptoms, Diagnosis, and Complications
515
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
515
Pathophysiology of Diabetes
894
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
894
Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181
Diabetes: Management and Pharmacotherapy
243
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
243


